☰

Chelsea M. Byrd, Ph.D. - Publications

Affiliations: 
2005 Oregon State University, Corvallis, OR 
Area:
Molecular Biology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Scaturro P, Trist IM, Paul D, Kumar A, Acosta EG, Byrd CM, Jordan R, Brancale A, Bartenschlager R. Characterization of the mode of action of a potent dengue virus capsid inhibitor. Journal of Virology. 88: 11540-55. PMID 25056895 DOI: 10.1128/Jvi.01745-14  0.485
2013 Byrd CM, Grosenbach DW, Hruby DE. Antiviral options for biodefense. Current Opinion in Virology. 3: 537-41. PMID 23773331 DOI: 10.1016/J.Coviro.2013.05.020  0.571
2013 Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, et al. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrobial Agents and Chemotherapy. 57: 1902-12. PMID 23403421 DOI: 10.1128/Aac.02251-12  0.684
2013 Santos-Fernandes É, Beltrame CO, Byrd CM, Cardwell KB, Schnellrath LC, Medaglia ML, Hruby DE, Jordan R, Damaso CR. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®. Antiviral Research. 97: 301-11. PMID 23257396 DOI: 10.1016/J.Antiviral.2012.11.010  0.664
2013 Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, Schneider C, Wineinger KA, Page JM, Harver C, Stavale E, Tyavanagimatt S, Stone MA, Bartenschlager R, Scaturro P, et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrobial Agents and Chemotherapy. 57: 15-25. PMID 23070172 DOI: 10.1128/Aac.01429-12  0.645
2013 Byrd CM, Bolken TC, Hruby DE. Vaccinia Virus Cysteine Proteinase Handbook of Proteolytic Enzymes. 2: 2390-2392. DOI: 10.1016/B978-0-12-382219-2.00533-0  0.66
2013 Byrd CM, Bolken TC, Hruby DE. Vaccinia Virus Metalloproteinase Handbook of Proteolytic Enzymes. 1: 1462-1464. DOI: 10.1016/B978-0-12-382219-2.00329-X  0.65
2012 Byrd CM, Hruby DE. Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV. Methods in Molecular Biology (Clifton, N.J.). 890: 113-21. PMID 22688763 DOI: 10.1007/978-1-61779-876-4_6  0.678
2010 Byrd C, Harver C, Cardwell K, Grosenbach D, Berhanu A, Dai D, Hruby D, Jordan R. Small Molecule Inhibitors of Dengue Virus Replication are Active In Vivo Antiviral Research. 86: A30-A31. DOI: 10.1016/J.Antiviral.2010.02.364  0.668
2010 Byrd CM, Hruby DE. Need for dengue virus drug discovery Handbook of Disease Outbreaks: Prevention, Detection and Control. 343-349.  0.666
2009 Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, Hruby DE, Jordan R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virology Journal. 6: 44. PMID 19400954 DOI: 10.1186/1743-422X-6-44  0.636
2009 Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrobial Agents and Chemotherapy. 53: 2620-5. PMID 19349521 DOI: 10.1128/Aac.00021-09  0.672
2009 Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrobial Agents and Chemotherapy. 53: 1817-22. PMID 19223621 DOI: 10.1128/Aac.01596-08  0.555
2009 Byrd C, Page J, Harver C, Grosenbach D, Berhanu A, Hruby D, Jordan R. Novel Small Molecule Inhibitors of Dengue Virus Replication Antiviral Research. 82: A38. DOI: 10.1016/J.Antiviral.2009.02.078  0.668
2008 Byrd CM, Page J, Hruby DE, Jordan R. Orthopoxvirus: Biology, pathology and therapy Drugs of the Future. 33: 875-890. DOI: 10.1358/dof.2008.33.10.1238226  0.552
2007 Katritch V, Byrd CM, Tseitin V, Dai D, Raush E, Totrov M, Abagyan R, Jordan R, Hruby DE. Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches. Journal of Computer-Aided Molecular Design. 21: 549-58. PMID 17960327 DOI: 10.1007/S10822-007-9138-7  0.575
2007 BYRD C, STAVALE E, WIECZOREK A, TRAN T, HRUBY D, JORDAN R. Discovery of Novel Small Molecule Inhibitors of Dengue Virus Replication Antiviral Research. 74: A77-A77. DOI: 10.1016/J.Antiviral.2007.01.130  0.667
2006 Moerdyk MJ, Byrd CM, Hruby DE. Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains. Virology Journal. 3: 64. PMID 16945137 DOI: 10.1186/1743-422X-3-64  0.603
2006 Byrd CM, Hruby DE. Vaccinia virus proteolysis--a review. Reviews in Medical Virology. 16: 187-202. PMID 16710840 DOI: 10.1002/Rmv.499  0.668
2006 Honeychurch KM, Byrd CM, Hruby DE. Mutational analysis of the potential catalytic residues of the VV G1L metalloproteinase. Virology Journal. 3: 7. PMID 16504157 DOI: 10.1186/1743-422X-3-7  0.605
2006 Hruby DE, Byrd CM. Less is more: Poxvirus proteolysis Microbe. 1: 70-75. DOI: 10.1128/Microbe.1.70.1  0.648
2006 Byrd CM, Hruby DE. Viral proteinases: Targets of opportunity Drug Development Research. 67: 501-510. DOI: 10.1002/Ddr.20114  0.62
2005 Blouch RE, Byrd CM, Hruby DE. Importance of disulphide bonds for vaccinia virus L1R protein function. Virology Journal. 2: 91. PMID 16336686 DOI: 10.1186/1743-422X-2-91  0.642
2005 Byrd CM, Hruby DE. Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity. Virology Journal. 2: 63. PMID 16105175 DOI: 10.1186/1743-422X-2-63  0.632
2005 Byrd CM, Hruby DE. A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virology Journal. 2: 4. PMID 15701171 DOI: 10.1186/1743-422X-2-4  0.638
2004 Byrd CM, Bolken TC, Mjalli AM, Arimilli MN, Andrews RC, Rothlein R, Andrea T, Rao M, Owens KL, Hruby DE. New class of orthopoxvirus antiviral drugs that block viral maturation. Journal of Virology. 78: 12147-56. PMID 15507601 DOI: 10.1128/Jvi.78.22.12147-12156.2004  0.653
2004 Hedengren-Olcott M, Byrd CM, Watson J, Hruby DE. The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo. Journal of Virology. 78: 9947-53. PMID 15331728 DOI: 10.1128/Jvi.78.18.9947-9953.2004  0.689
2004 Byrd CM, Hruby DE. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods in Molecular Biology (Clifton, N.J.). 269: 31-40. PMID 15114005 DOI: 10.1385/1-59259-789-0:031  0.615
2003 Byrd CM, Bolken TC, Hruby DE. Molecular dissection of the vaccinia virus I7L core protein proteinase. Journal of Virology. 77: 11279-83. PMID 14512576 DOI: 10.1128/Jvi.77.20.11279-11283.2003  0.638
2002 Byrd CM, Bolken TC, Hruby DE. The vaccinia virus I7L gene product is the core protein proteinase. Journal of Virology. 76: 8973-6. PMID 12163618 DOI: 10.1128/Jvi.76.17.8973-8976.2002  0.642
2002 Byrd CM, Bolken TC, Jones KF, Warren TK, Vella AT, McDonald J, King D, Blackwood Z, Hruby DE. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine. 20: 2197-205. PMID 12009273 DOI: 10.1016/S0264-410X(02)00144-5  0.68
Show low-probability matches.